SS-31 + MOTS-c
Everyone agrees on the order. The reason they give for it is wrong.
The standard advice is SS-31 first, MOTS-c second, because SS-31 repairs the mitochondrial membrane and MOTS-c then builds on a healthy foundation. SS-31 does not repair the membrane. It holds damaged material in place while it is present, which changes what the sequence is doing.
Fix the engine before adding the supercharger.
That metaphor, or one very like it, appears on almost every page selling this pair.[1] The argument runs that mitochondria fail structurally first, so repairing the structure has to come before asking them to work harder.
It is a compelling story and it is why this stack gets run as a sequence rather than a pair. Protocols specify SS-31 in the morning and MOTS-c a couple of hours later, or SS-31 for a period before MOTS-c is introduced at all.[2]
The underlying complaint is specific: energy that has dropped without an obvious cause, slower recovery, and the sense that something upstream of willpower has changed.
Four benefits, and how well each one holds up.
The second row is the one that matters, because every argument for the sequence depends on it being true.
Three questions, answered before anything else.
SS-31 does not repair anything.
Cardiolipin is a fat found only in the inner mitochondrial membrane, and it holds the electron transport machinery in position. When it oxidises, that machinery drifts apart and electrons leak, and the leak produces more oxidation in a self-reinforcing loop.[3]
SS-31 binds cardiolipin and pulls those components back into proximity, restoring the arrangement without addressing the lipid itself.[3]
The primary literature uses the same language. Szeto's 2014 review, the paper this whole field is built on, is titled "First-in-class cardiolipin-protective compound".[9] Its abstract describes SS-31 binding selectively to cardiolipin and protecting the electron-carrying function of cytochrome c. It does not describe repair.
A clinical trial protocol for elamipretide puts it the same way, saying the compound is believed to stabilise cardiolipin in the mitochondrial membrane.[10] An independent research assessment describes it as binding cardiolipin and modulating the interaction between cytochrome c and cardiolipin.[11]
Protect, stabilise, modulate. Three independent descriptions, none of them repair. The word appears in the protocols selling the sequence and nowhere in the science underneath them.
That is not a small correction to the metaphor. The engine analogy says the repair is done and the foundation is now sound. What happens instead is that the damaged part is held in place for as long as the compound is present.
So a sequence built on "repair first, then build" amounts to "prop up, then build, while the propping continues". Whether that still justifies an order is a fair question. It is a different question from the one the protocols answer.
One specific claim deserves more scrutiny than it gets. Several sources state that new mitochondria built by MOTS-c would inherit defective membranes if SS-31 has not gone first.[2] Mitochondrial biogenesis synthesises new lipid. None of those sources cites a study showing inheritance of the defect, and we could not find one.
Confidently stated, and not agreed on.
Pages describing this sequence use phrases like current best practice. Set them side by side and the practice is not settled.
Repair and protect the existing membrane, then signal for more capacity on a sounder base.[1]
Some protocols separate the two by a couple of hours on the same morning. Others run SS-31 for weeks before introducing MOTS-c at all.[2]
Build more mitochondria first, then protect what you have built. One source frames SS-31 as the deeper intervention to add after MOTS-c has produced gains.[4]
Same two compounds, opposite order, equally confident.
The gaps between doses vary too, and none of the sources giving a specific interval explains where it came from. No pharmacokinetic argument is offered, and no trial has compared any ordering against any other.
When two sets of instructions contradict each other and neither cites evidence, what is being conveyed is confidence rather than a finding.
Stagger them so you can tell which one did anything.
One source makes an argument for sequencing that has nothing to do with mitochondrial biology, and it is the strongest one available.
Starting both compounds on the same day makes a weak experiment. If energy, sleep, glucose or recovery changes, there is no way to tell whether it came from cardiolipin stabilisation, AMPK signalling, a lifestyle change, or some interaction.[5]
Introducing one at a time is the only way to attribute anything. That argument works regardless of which order you pick, which is precisely why it is more useful than the mechanistic story.
It also sets a low bar that almost nobody meets. Attribution requires measuring something before starting, waiting long enough for a change to appear, and not altering anything else. Most people change three things at once and credit whichever compound they read about most recently.
One approval, one negative trial, one answer pending.
SS-31 is the only compound here with an approval. It was granted accelerated approval as Forzinity in September 2025 for Barth syndrome, a rare inherited disease in which cardiolipin remodelling is defective.[6] That makes it the first mitochondria-targeted drug ever approved, and the approval is conditional on a confirmatory trial still recruiting.
Its largest trial in a broader population found nothing. A 218-patient Phase 3 measured walking distance in people with a mitochondrial disease and found a difference against placebo of minus 3.2 metres. Fatigue showed no benefit either. The three-compound page covers that trial in full.
MOTS-c has no completed human efficacy trial. Its first began on 2 February 2026 in adults with prediabetes and excess weight, and reports around February 2027.[7] That page covers it, including the finding that one bike session raises natural MOTS-c about twelvefold.
Neither compound has been tested alongside the other, in either order.
Two vials, and no premixed version.
Nobody sells this pair ready-mixed, which suits a stack meant to be staggered. Bought separately the two come to $59.54 at the cheapest in-stock listings.[8]
Both have very wide price spreads. SS-31 runs from $31.99 to $1,147.13 and MOTS-c from $27.55 to $784.99, so the compound matters less than where you buy it.
Adding NAD+ makes it the three-compound mitochondrial stack. Swapping SS-31 for 5-Amino-1MQ makes it a premixed blend sold as MitoPrime, which costs about 2.6 times its own parts.
One approval that does not cover this, and one ban.
SS-31's approval as Forzinity covers Barth syndrome. It does not authorise use for fatigue, longevity, performance or general mitochondrial support, and research-grade SS-31 is a different product from the approved drug.[5]
MOTS-c has no approval anywhere and no classification on the FDA's 503A list, the register of ingredients compounding pharmacies may work with, meaning it has not been assessed either way.
MOTS-c is banned at all times by WADA as an AMPK activator. Any tested athlete taking this pair has committed a doping violation regardless of the order.
There is no human safety data for injected MOTS-c, and SS-31's safety record comes from trial populations with mitochondrial disease rather than healthy adults.
What people ask about this stack
Should SS-31 come before MOTS-c?
Most sources say yes and none of them cites a study. The stated reason is that SS-31 repairs the membrane so MOTS-c can build on a healthy foundation. That reason is inaccurate. SS-31 stabilises damaged cardiolipin while it is present rather than repairing or replacing it. At least one source argues the opposite order, MOTS-c first to build capacity, then SS-31 to protect it. No trial has compared any ordering against any other.
What does SS-31 do?
SS-31 binds cardiolipin, a fat found only in the inner mitochondrial membrane, and pulls the electron transport components back into position. That improves the arrangement while the compound is present. It does not repair the oxidised lipid or replace it, so the underlying damage remains. One clinician writing about this sequence states that directly, and the primary literature agrees. Szeto's 2014 review calls SS-31 a cardiolipin-protective compound, and a trial protocol describes it as believed to stabilise cardiolipin.
Is there any good reason to stagger them?
One, and it has nothing to do with mitochondria. Starting both at once means any change in energy, sleep or recovery cannot be attributed to either compound, to a lifestyle change, or to an interaction. Introducing one at a time is the only way to tell what did anything. That argument holds whichever order you choose.
Does either compound work for energy?
SS-31's largest trial measured walking distance in 218 patients with a mitochondrial disease and found a difference against placebo of minus 3.2 metres, with no benefit on fatigue either. MOTS-c has no completed human efficacy trial; its first began in February 2026 and reports around February 2027. SS-31 does hold an accelerated FDA approval as Forzinity, for Barth syndrome specifically.
Can athletes take this?
No. MOTS-c is banned at all times by WADA as an AMPK activator, which covers compounds that switch on the cell's low-energy response. A tested athlete taking this pair has committed a doping violation regardless of sequence or dose.
What does adding NAD+ change?
Adding NAD+ makes this the three-compound mitochondrial stack, where NAD+ supplies the coenzyme both processes use. That page covers the combination, including the trial evidence for all three. A different premixed blend swaps SS-31 for 5-Amino-1MQ, a compound with no human trials of any kind. Compare against the other stacks.
What this page is built on
- 01Sequencing guides recommending SS-31 before MOTS-c, framed as repair before optimisation and as fixing an engine before adding a supercharger. Source for the claim being described as current best practice.
- 02Protocol pages specifying the interval between the two compounds and the claim that new mitochondria would inherit defective membrane characteristics if SS-31 has not gone first.
- 03Sawicki K. Should you run SS-31 before MOTS-c? Source for SS-31 binding cardiolipin and drawing electron transport complexes back into proximity, for the self-reinforcing loop between cardiolipin oxidation and electron leakage, and for the statement that SS-31 does not repair or replace the damaged lipid but works around the damage by temporarily stabilising what is already there. Figure adapted from Szeto HH, British Journal of Pharmacology, 2014.
- 04A source arguing the reverse order, MOTS-c first for biogenesis and SS-31 afterwards for protection, framing SS-31 as the deeper intervention to add once MOTS-c has produced gains.
- 05Source for the attribution argument, that starting both compounds together makes a weak experiment because any change cannot be traced to cardiolipin stabilisation, AMPK signalling, lifestyle change or interaction. Also the source for SS-31's approval not authorising use for fatigue, longevity, performance or general mitochondrial optimisation, and for research-grade SS-31 differing from the approved product.
- 06SS-31, as elamipretide, granted FDA accelerated approval as Forzinity in September 2025 for Barth syndrome, a rare genetic disorder defined by defective cardiolipin remodelling. First mitochondria-targeted therapeutic to receive FDA approval.
- 07MOTS-MET, Phase 2a in adults with prediabetes and overweight or obesity. NCT07505745. Started 2 February 2026, primary completion estimated 14 February 2027.
- 09Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 2014;171(8):2029-50. PMID 24117165, DOI 10.1111/bph.12461. SS-31 binds selectively to cardiolipin through electrostatic and hydrophobic interactions, preventing cardiolipin from converting cytochrome c into a peroxidase while protecting its electron-carrying function.
- 10Investigator-initiated study protocol for elamipretide in Friedreich's ataxia. NCT05168774. Describes elamipretide as believed to stabilise cardiolipin in the mitochondrial membrane, leading to improved mitochondrial function and decreased reactive oxygen species.
- 11SS-31 assessment, Alzheimer's Drug Discovery Foundation Cognitive Vitality. Report PDF. Describes SS-31 binding cardiolipin, modulating the interaction between cytochrome c and cardiolipin, promoting the electron-carrying function of cytochrome c, and inhibiting opening of the mitochondrial permeability transition pore.
- 08Peptide Decoding vendor pricing data, 26 September 2026. Lowest in-stock single-compound listings: SS-31 $31.99 across 42 listings, ranging to $1,147.13; MOTS-c $27.55 across 119 listings, ranging to $784.99. No premixed listing combining the two.